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Introduction
Apoptosis is a well-orchestrated process regulated by multiple 
genes, particularly those belonging to the BCL-2 family. The inher-
ent ability of cells to undergo apoptosis in response to cellular 
stresses, including activation of oncogenes such as MYC, functions 
as a safeguard against tumorigenesis (1). Consequently, alterations 
resulting in aberrant expression of antiapoptotic BCL-2 family 
members and/or loss of expression of proapoptotic BCL-2 family 
members are well documented in most human cancers (2). The 
BCL-2 family has an established role in determining whether cells 
should live or die. However, knowledge about whether specific 
BCL-2 family members (other than BCL-2 itself) are dysregulated 
in or contribute to human malignancies and how this information 
can be exploited therapeutically remains incomplete.
Dysregulated MYC expression occurs in at least 70% of human 
malignancies and is a known driver of Burkitt lymphoma (BL) (3). 
The Eμ-MYC–Tg mouse model of MYC-induced B cell lymphoma-
genesis (4) has been instrumental in delineating the roles of BCL-2 
family proteins in lymphoma, which has translated to many other 
human cancers (5). However, relative to other BCL-2 family mem-
bers, little information is known about the role of the antiapoptotic 
protein BCL-W in cell survival and lymphomagenesis. This is like-
ly due to early reports showing low expression of BCL-W in pri-
mary mouse hematopoietic cells and to observations that Bcl-w–
deficient mice have no overt hematopoietic defects (6, 7). While 
BCL-W is recognized for its critical function in spermatogenesis 
(8, 9), there is emerging evidence to suggest that BCL-W may also 
have a role in tumorigenesis. Specifically, BCL-W overexpression 
cooperated with MYC to accelerate the development of myeloid 
leukemia (10). In addition, BCL-W overexpression was observed 
in patient samples of gastric and colorectal adenocarcinoma (11, 
12) and in several human solid tumor cell lines (13). These data 
indicate that BCL-W may contribute to human cancers, but which 
malignancies and whether BCL-W contributes to tumorigenesis 
and cancer cell survival remain unclear.
Here, we report a previously unknown role for BCL-W in 
MYC-induced apoptosis and lymphomagenesis that we believe will 
have significant clinical implications. By evaluating BCL-W expres-
sion in human B cell lymphomas in combination with mouse mod-
eling to directly assess the contribution of BCL-W in MYC-driven 
lymphomagenesis, we determined that BCL-W has a significant 
role in B cell lymphoma development and survival. Furthermore, 
we identified a mechanism by which MYC regulates BCL-W expres-
sion. Our data illuminate an unappreciated link between MYC and 
BCL-W that we believe significantly extends the knowledge of MYC 
and the role of BCL-W in tumorigenesis, both of which should aid 
in improving lymphoma prognostics, diagnostics, and therapeutics.
Results
Cytokine deprivation–induced apoptosis is accelerated by loss of BCL-W. 
BCL-W levels were reported to be low in lymphocytes and dispens-
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totic stimuli such as hyperproliferative signals from oncogenes 
like MYC, we induced the expression of a 4-hydroxytamoxifen–
inducible (4-OHT–inducible) form of MYC (MYCER) (14) in pri-
mary pre–B cell cultures from littermates (Figure 2A). Following 
activation of MYCER with 4-OHT, we observed a robust apoptotic 
response in pre–B cells lacking both alleles of Bcl-w. There was a 
decrease in cell growth (Figure 2A), total cell numbers (Figure 2B), 
and viability (Figure 2C) in the MYCER-activated Bcl-w–/– pre–B 
cells compared with WT pre–B cells. Moreover, the Bcl-w–null 
pre–B cells showed an increase in annexin V–positive cells (Figure 
2D) and a more rapid appearance of cleaved caspase 3 (Figure 2E) 
following MYCER activation. We observed a modest, but signif-
icant, decrease in cell growth and survival in Bcl-w+/– pre–B cells 
compared with WT pre–B cells following MYCER activation (Fig-
ure 2, A–E). These data demonstrate that BCL-W is critical for B 
cell survival in the presence of MYC dysregulation.
To further test the role of BCL-W in MYC-induced apop-
tosis in B cells, we derived pre–B cells from the BM of litter-
mate-matched Bcl-w+/+, Bcl-w+/–, and Bcl-w–/– Eμ-MYC mice, which 
overexpress MYC specifically in B cells (4), prior to any sign of 
lymphoma development. Within 12 days after explantation into 
culture, pre–B cells (B220+CD19+CD43–IgM–) dominated the cul-
able for lymphocyte survival due to a lack of defects in Bcl-w–null 
mice (6–8). However, we directly tested whether BCL-W contribut-
ed to the survival of B cells by generating cultures of primary pre–B 
cells isolated from BM of littermate-matched Bcl-w+/+, Bcl-w+/–, and 
Bcl-w–/– mice. BCL-W protein was readily detectable in WT pre–B 
cells (Figure 1A). BCL-W levels decreased by approximately half 
with loss of 1 allele of Bcl-w and were absent in the Bcl-w–null pre–B 
cells. The levels of other antiapoptotic BCL-2 family members were 
unaltered in the Bcl-w–deficient cells (Figure 1A). The growth rates 
and viability of the 3 genotypes of pre–B cells cultured under normal 
conditions were indistinguishable from each other (Figure 1, B–D). 
However, loss of Bcl-w affected cell survival following withdrawal 
of IL-7, an essential cytokine. Specifically, Bcl-w–null pre–B cells had 
significantly reduced cell expansion following IL-7 withdrawal, due 
to decreased cell numbers and viability (Figure 1E). Bcl-w heterozy-
gous pre–B cells showed an intermediate reduction in growth and 
survival compared with WT and Bcl-w–/– pre–B cells after IL-7 with-
drawal (Figure 1E). These results indicate that a loss of Bcl-w poten-
tiates the negative consequences of cytokine deprivation in B cells 
and that BCL-W contributes to B cell survival.
MYC-induced apoptosis is augmented by loss of BCL-W. To deter-
mine whether loss of Bcl-w would confer sensitivity to other apop-
Figure 1. Cytokine deprivation–induced pre–B cell death is accelerated by loss of Bcl-w. BM from Bcl-w+/+, Bcl-w+/–, and Bcl-w–/– littermates was placed 
into IL-7–containing media on day 0. Western blotting was performed on pre–B cells that grew out of the cultures (A). Cells were counted at intervals, 
population doublings were calculated (B), and viability (C) was determined by trypan blue dye exclusion. (D and E) Equal numbers of pre–B cells of each 
genotype were plated with (D) or without (E) IL-7. MTS assays were performed in quadruplicate at intervals (left, D and E). Total viable cell numbers (mid-
dle, D and E) and viability (right, D and E) were measured with trypan blue in triplicate at the indicated intervals. Data shown are representative results of 2 
to 4 independent experiments from cells isolated from 2 separate litters generated by different parents. Error bars indicate the SD. For E, *P < 0.0001,  
#P < 0.0004, and §P < 0.0009, by 1-way ANOVA.
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obtained similar results when equal numbers of Eμ-MYC pre–B 
cells from each genotype were cultured and evaluated each day 
for 6 days (Figure 2H).
At intervals throughout the duration of these experiments, we 
assessed Eμ-MYC pre–B cells of each genotype for characteristics 
of apoptosis. We determined that loss of Bcl-w led to a significant 
increase in apoptosis over time compared with the WT counter-
part, as evidenced by an increased number of annexin V–positive 
cells (Figure 2I) and the appearance of cleaved caspase 3 (Figure 
2J). In addition, Bcl-w+/–Eμ-MYC pre–B cells also showed an ele-
tures for all 3 genotypes (Supplemental Figure 1; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI89486DS1), indicating that loss of Bcl-w did not impair the 
ability of BM cells to differentiate into pre–B cells when MYC was 
overexpressed. However, when we evaluated pre–B cell growth 
by assessing the net population doublings beginning the day BM 
was isolated, we determined that Bcl-w–/– Eμ-MYC pre–B cells were 
unable to expand in culture (Figure 2F) due to decreased viabili-
ty (Figure 2G). Even loss of 1 Bcl-w allele was sufficient to impair 
Eμ-MYC pre–B cell growth and survival (Figure 2, F and G). We 
Figure 2. MYC-induced apoptosis is augmented by loss of Bcl-w. (A–E) BM-derived pre–B cells from Bcl-w+/+, Bcl-w+/–, and Bcl-w–/– littermates were infected 
with the 4-OHT–inducible MYCER. Western blot analysis was performed (A). Equal numbers of cells of each genotype were placed into culture. Following the 
addition of 4-OHT to activate MYCER, MTS assays (A) were performed in quadruplicate, total viable cell numbers (B) and viability (C) were determined using 
trypan blue dye (in triplicate), and annexin V positivity (in triplicate) (D) and caspase 3 cleavage (CC3) (E) were evaluated. (F–J) BM from Bcl-w+/+ Eμ-MYC, 
Bcl-w+/– Eμ-MYC, and Bcl-w–/– Eμ-MYC–Tg littermates prior to any detectable lymphoma was placed into culture on day 0, and cells were counted at inter-
vals. Western blot analysis was performed on the pre–B cells that grew out of the cultures (F). Population doublings were calculated (F) and viability was 
determined by trypan blue dye exclusion (G). (H) Equal numbers of pre–B cells of each genotype were plated and MTS assays (quadruplicate) performed. (I 
and J) At the indicated intervals, cells were collected and annexin V positivity (I) and cleaved caspase 3 (J) assessed. Data shown are representative of 3 to 4 
independent experiments using cells isolated from 3 separate litters generated by different parents. Error bars indicate the SD. *P < 0.0001 for A, *P < 0.029 
for B, *P < 0.003 for C, *P < 0.028 for D (comparing 4-OHT–treated samples), *P < 0.0001 for H, and *P < 0.0002 for I, by 1-way ANOVA.
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or no Bcl-w alleles. Bcl-w–/– Eμ-MYC mice had an extremely long 
delay in lymphoma development (Figure 3A; P < 0.0001, log-rank 
test). This delay in MYC-induced lymphomagenesis resulted in a 
mean survival of 298.5 days for Bcl-w–/– Eμ-MYC mice, which was 
3.3 times longer than the mean survival of their Bcl-w+/+ Eμ-MYC 
littermates (90.0 days). Of note, all of the Bcl-w+/+ Eμ-MYC mice 
developed lymphoma and were sacrificed before the first Bcl-w–/– 
Eμ-MYC mouse presented with lymphoma. Loss of just 1 Bcl-w 
allele also significantly delayed MYC-induced B cell lymphoma 
development (Figure 3A; P = 0.0338, log-rank test; mean surviv-
al of 120.7 days). Immunophenotyping revealed no difference in 
the type of B cell lymphomas that arose. Specifically, all 3 geno-
types developed lymphomas characteristic of those that develop 
in Eμ-MYC–Tg mice (15), with a similar distribution of pre–B cell 
(B220+CD19+CD43–IgM–), B cell (B220+CD19+CD43–IgM+), and 
pre–B/B cell lymphomas (Figure 3B), including lymphomas that 
arose early or late. Therefore, a deficiency in Bcl-w caused a delay 
in B cell lymphoma development, but did not alter the type of lym-
phoma that emerged.
vated apoptotic index, as these cultures had increased annexin V 
staining (Figure 2I) and caspase 3 cleavage (Figure 2J) compared 
with Bcl-w+/+ Eμ-MYC pre–B cell cultures. These results further 
demonstrate that BCL-W has an essential role in B cell survival 
and inhibition of MYC-induced apoptosis.
To assess whether the effects of loss of Bcl-w following 
MYC dysregulation were B cell specific, we evaluated MYCER- 
expressing murine embryonic fibroblasts (MEFs). First, we 
assessed whether a deficiency in Bcl-w altered the response 
to MYCER activation under normal growth conditions (full 
serum). While WT MEFs had decreased growth and viability and 
increased apoptosis following MYCER activation, the effects 
were more robust in Bcl-w–null MEFs (Supplemental Figure 2, 
A–F). The apoptotic response was also accelerated in Bcl-w het-
erozygous MEFs following MYCER activation compared with 
the response observed in Bcl-w+/+ MEFs (Supplemental Figure 
2, A–F). Under serum-free conditions, Bcl-w–null MEFs rapidly 
underwent apoptosis following MYCER activation (Supplemen-
tal Figure 2, A–C). After only 24 hours of MYCER activation, no 
viable cells remained in the Bcl-w–/– MEF cultures, whereas a third 
of their WT counterparts were still viable. Together, these results 
show that BCL-W is not only important for the survival of B cells, 
but also contributes significantly to the survival of nonhemato-
poietic cells in response to dysregulated MYC.
Loss of BCL-W profoundly delays MYC-driven lymphoma devel-
opment. Given that loss of Bcl-w substantially increased the sus-
ceptibility of B cells to MYC-induced apoptosis, we postulated 
that a deficiency in Bcl-w would negatively affect MYC-driven B 
cell lymphoma development. To test this hypothesis, we gener-
ated a cohort of littermate-matched Eμ-MYC–Tg mice with 2, 1, 
Figure 3. Loss of Bcl-w profoundly delays MYC-driven lymphomagenesis. (A) Kaplan-Meier survival curves of Bcl-w+/+ Eμ-MYC, Bcl-w+/– Eμ-MYC, and 
Bcl-w–/– Eμ-MYC–Tg mice. P < 0.0001, comparing all 3 genotypes with each other; P < 0.0001, comparing Bcl-w–/– Eμ-MYC with Bcl-w+/+ Eμ-MYC; P = 0.0338, 
comparing Bcl-w+/– Eμ-MYC with Bcl-w+/+Eμ-MYC, by log-rank test. (B and C) Lymphomas of the indicated genotypes were subjected to (B) immunopheno-
typing to determine the type of lymphoma that emerged and (C) Western blotting to determine p53 and ARF status. Controls included a lymphoma- 
containing mutant p53 and p53–/– Mdm2–/– MEFs. Representative Western blots are shown; additional blots are shown in Supplemental Figure 4A. Sum-
marized results of Western and Southern blotting are provided in Table 1.
Table 1. Reduced ARF and p53 inactivation in Bcl-w–deficient 
lymphomas
Genotype p53-mutatedA p53-deletedB Arf-deletedB
Bcl-w+/+ Eμ-MYC 2 of 10 (20%) 0 of 10 (0%) 2 of 10 (20%)
Bcl-w+/– Eμ-MYC 1 of 15 (7%) 0 of 15 (0%) 2 of 15 (13%)
Bcl-w–/– Eμ-MYC 1 of 20 (5%) 0 of 20 (0%) 2 of 20 (10%)
ADetermined by sequencing; Bdetermined by Southern blotting.
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numbers at all stages of development 
in the BM of Bcl-w–deficient Eμ-MYC 
mice (Supplemental Figure 3B). Eval-
uation of littermate-matched, non-
Tg mice showed analogous results 
among the 3 genotypes (Supplemen-
tal Figure 3, A and B). Therefore, a 
deficiency in Bcl-w does not appear to 
alter B cell development in mice with 
normal or increased levels of MYC.
MYC overexpression selects 
for inactivation of the ARF/p53 
tumor-suppressor pathway during 
lymphomagenesis, and alterations in 
proteins that influence apoptosis can 
change the frequency of ARF and/or 
p53 inactivation (16–18). To assess 
whether loss of Bcl-w affected the 
frequency of ARF and/or p53 inacti-
vation, we performed Western (Fig-
ure 3C and Supplemental Figure 4A) 
and Southern (Supplemental Figure 
4B) blot analyses of lymphomas from 
mice of all 3 genotypes. As muta-
tions in p53 typically result in protein 
overexpression (16), we performed 
sequencing of p53 on samples that 
showed increased levels of p53 pro-
tein. We also sequenced p53 in lym-
phomas with increased ARF protein due to the negative feedback 
regulation of ARF by p53. Only lymphomas with elevated p53 pro-
tein harbored mutations in the DNA-binding domain of p53, the 
most frequently mutated region in p53 (19). Loss of Bcl-w resulted 
in less frequent mutations of p53 (Table 1). p53 deletions are rare 
in Eμ-MYC–Tg mice, and we detected no p53 deletions in any of 
the lymphomas from mice of the 3 genotypes (Table 1 and Sup-
plemental Figure 4B). We observed a decrease in the frequency of 
To determine whether the protracted latency of lymphoma 
development in mice lacking Bcl-w was due to a deficiency in B 
cells, we performed immunophenotyping on 4 independent sets 
of littermate-matched precancerous Eμ-MYC mice to evaluate B 
cell populations. The data show no difference in the number of B 
cells in the spleens of Bcl-w–/– Eμ-MYC or Bcl-w+/– Eμ-MYC mice 
compared with their WT Eμ-MYC littermates (Supplemental Fig-
ure 3A). Similarly, there was no discernible difference in B cell 
Figure 4. MYC suppresses BCL-W 
expression in normal cells. At intervals 
following the addition of 4-OHT, WT 
pre–B cells (A, left) and p53-null MEFs 
(C–E) expressing either WT MYCER (A, 
left, B, top, C, and D), MYCV394D-ER (C), 
or MYCΔMBII-ER (D and E) were Western 
blotted for the indicated proteins (A, C, 
and D), and mRNA levels were measured 
in triplicate by qRT-PCR (B, top, and E). 
Precancerous splenocytes from Eμ-MYC–
Tg (Tg+) and non-Tg littermates (Tg–) were 
subjected to Western blotting (A, right) 
and qRT-PCR (in triplicate, B, bottom; 
n = 4 of each). mRNA expression was 
normalized to β-actin and presented as 
2–ΔΔCt. Data shown are representative of 2 
to 4 independent experiments. Error bars 
indicate the SEM. *P < 0.0071 (B) and  
*P < 0.005 (E), by t test.
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Arf deletions in lymphomas that lacked Bcl-w (Table 1 and Supple-
mental Figure 4B). Together, these results suggest that, without 
Bcl-w, the selective pressure to inactivate the ARF/p53 pathway 
was reduced during lymphomagenesis.
MYC suppresses BCL-W expression. MYC activates apoptosis 
by activating p53, but also by suppressing the expression of BCL-2 
and/or BCL-XL independently of p53 (20–23). We investigated 
whether BCL-W expression was regulated by MYC by expressing 
MYCER in pre–B cells. Activation of MYCER with the addition of 
4-OHT decreased BCL-W as well as BCL-2 and BCL-XL protein 
levels (Figure 4A, left). Consistent with previous reports (20, 23), 
protein levels of the antiapoptotic BCL-2 family member MCL-1 
did not change following MYCER activation (Figure 4A, left). As 
a separate, independent test of MYC regulation and to determine 
whether MYC regulates BCL-W expression in vivo, we evaluated 
spleens from precancerous Eμ-MYC mice and littermate-matched 
non-Tg spleens. Eμ-MYC spleens had reduced BCL-W protein 
levels as well as decreased BCL-2 and BCL-XL, but MCL-1 lev-
els were unchanged compared with levels detected in the litter-
mate-matched non-Tg spleens (Figure 4A, right). Evaluation of 
Bcl-w mRNA by quantitative real-time PCR (qRT-PCR) showed 
that, following MYCER activation in pre–B cells, Bcl-w mRNA lev-
els decreased (Figure 4B, top panels). In addition, spleens from 
precancerous Eμ-MYC mice had reduced levels of Bcl-w mRNA 
compared with spleens from non-Tg littermates (Figure 4B, bot-
tom panels). Taken together, MYC induces a decrease in BCL-W 
mRNA and protein levels in B cells.
To determine whether the MYC-induced decrease in BCL-W 
was cell-type specific, we also assessed WT MEFs expressing 
MYCER. Analogous to the results we obtained in pre–B cells, 
activation of MYCER in these nonhematopoietic cells decreased 
BCL-W levels (Supplemental Figure 5). Likewise, BCL-2 and BCL-
XL levels were also reduced following MYCER activation (Sup-
plemental Figure 5). Therefore, the MYC-induced decrease in 
BCL-W also occurred in primary nonhematopoietic cells, indicat-
ing that this was a generalizable consequence of MYC activation.
Suppression of BCL-W expression is independent of MIZ-1 and 
p53, but requires MYC transcriptional activity. To gain insight into 
the mechanism by which MYC was modulating BCL-W expres-
sion, we performed a series of experiments using mutants of MYC. 
MYC can suppress the expression of some genes by inhibiting the 
transcriptional activator MIZ-1 (24). Using a mutant of MYCER 
containing a point mutation interrupting the MYC:MIZ-1 interac-
tion (MYCV394D-ER) (25), we determined that BCL-W protein 
levels decreased in cells expressing MYCV394D-ER to an extent 
similar to that seen in cells with WT MYCER following activation 
with 4-OHT (Figure 4C). We also observed analogous reductions 
of BCL-2 and BCL-XL, but not of MCL-1 (Figure 4C). To evalu-
ate whether a transcriptionally competent MYC was required to 
suppress BCL-W protein expression, we used a mutant of MYCER 
lacking the MYC box II domain, which is crucial for MYC transcrip-
tional activity (MYCΔMBII-ER) (24). Upon addition of 4-OHT, we 
observed a decrease in BCL-W protein only in cells expressing 
the WT MYCER, but not in cells expressing the transcriptionally 
impaired MYCΔMBII-ER mutant (Figure 4D). The decrease in 
BCL-W protein expression was reflected at the mRNA level, as a 
reduction in Bcl-w mRNA only occurred in cells expressing WT 
MYCER, but not the transcriptionally impaired MYCΔMBII-ER 
(Figure 4E). These data demonstrate that MYC transcriptional 
activity is required to downregulate BCL-W expression. Further-
more, the experiments using MYCER mutants were performed in 
cells lacking p53 (Figure 4, C–E), indicating that the MYC-induced 
decrease in BCL-W expression occurs independently of p53.
BCL-W expression is modulated by the MYC-regulated miR-15 
family. Upon evaluation of publically available ENCODE MYC 
ChIP-sequencing (ChIP-seq) data (26), MYC was not present at 
Figure 5. BCL-W expression is regulated by MYC 
through transcriptional upregulation of the miR-15 
family. (A–C) A luciferase reporter containing the 
3′-UTR of Bcl-w with a WT or mutated (Mut) miR-15 
family binding site was transfected into p53–/– MEFs 
expressing MYCER (A), MYCΔMBII-ER (B), or MYC-
V394D-ER (C). Luciferase activity was measured in 
triplicate 48 hours after the addition of vehicle con-
trol (EtOH) or 4-OHT. A luciferase reporter containing 
either the WT or mutated miR-15 family binding site 
of the 3′-UTR of Bcl-2 served as a positive control for 
A–C. A β-gal reporter was cotransfected for normal-
ization purposes. (C and D) miR-15 family binding 
sites in the 3′-UTR of Bcl-w and Bcl-2 were blocked 
with site-specific small molecules (Target Protectors 
[TP]) 24 hours prior to MYCV394D-ER activation. 
Following the addition of 4-OHT, luciferase activity (C) 
and protein levels (D) were assessed in the presence 
or absence of the Bcl-w and Bcl-2 Target Protectors. 
Data shown are representative of 2 to 4 independent 
experiments. Error bars indicate the SD. *P = 0.0017 
(A), by t test; *P < 0.0001 (B and C), by 1-way ANOVA.
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the Bcl-w promoter region in hematopoietic or nonhematopoietic 
cell lines (Supplemental Figure 6). Therefore, we postulated that 
MYC may be indirectly altering Bcl-w expression through miR. As 
we (Supplemental Figure 7) and others (27–29) have shown, Bcl-w 
mRNA is targeted and negatively regulated by the miR-15 family. 
Recently, we reported that MYC transcriptionally upregulates this 
miR family as a mechanism to downregulate Bcl-2 expression (22, 
23). To test whether MYC activation leads to miR-15 family target-
ing of Bcl-w, we used a luciferase-based assay to detect direct bind-
ing of the miR-15 family to its predicted target site in the 3′-UTR 
of Bcl-w following MYC-induced transcriptional upregulation. 
Specifically, luciferase reporters harboring either a WT miR-15 
family binding site of the Bcl-w 3′-UTR or a mutated version were 
introduced into p53–/– MEFs expressing the 4-OHT–inducible form 
of MYCER. Upon activation of MYCER, we detected a decrease in 
luciferase activity in cells containing the WT miR-15 family bind-
ing site, but not the mutated miR-15 family binding site (Figure 
5A). As a positive control, we evaluated cells with WT or mutated 
miR-15 family binding sites in the 3′-UTR of Bcl-2 and obtained 
results analogous to those with the Bcl-w 3′-UTR (Figure 5A). 
These results indicate that MYC induces the expression of miR-
15 family members, as we have recently reported (23), which then 
directly bind and negatively regulate Bcl-w expression.
To further assess the mechanism by which MYC regulates the 
miR-15 family to target Bcl-w, we used the transcriptionally incom-
petent form of MYC. p53-null MEFs expressing either the WT MYC-
ER or the deletion mutant MYCΔMBII-ER were transfected with a 
luciferase reporter containing the WT miR-15 family binding site 
of either the Bcl-w 3′-UTR or, as a positive control, the Bcl-2 3′-UTR. 
Following activation of WT MYCER, luciferase activity decreased 
in cells containing the Bcl-w or Bcl-2 3′-UTR (Figure 5B). In con-
trast, after addition of 4-OHT to the MYCΔMBII-ER–express-
ing cells, we detected no change in luciferase activity for either 
luciferase reporter (Figure 5B), indicating that a transcription-
ally competent MYC is required for the miR-15 family–mediated 
decrease in Bcl-w expression.
We further validated this MYC-regulated miR-mediated 
mechanism by transfecting p53-null MEFs expressing the MYC-
ER mutant unable to interact with MIZ-1 (MYCV394D-ER) with 
modified RNA molecules (Target Protectors) designed to block 
endogenous miR-15 family members from binding their target 
site in the 3′-UTR of Bcl-w. In addition to the Target Protectors, 
the MYCV394D-ER–expressing cells received luciferase reporters 
containing the miR-15 family binding site for either the 3′-UTR of 
Bcl-w or, as a control, Bcl-2. In the absence of any Target Protec-
tors, MYCV394D-ER activation, which upregulates the miR-15 
family (23), resulted in decreased luciferase activity in cells with 
either the Bcl-w or Bcl-2 luciferase reporters (Figure 5C). However, 
when the miR-15 family binding site of the Bcl-w or Bcl-2 3′-UTR 
was blocked by their respective Target Protectors, luciferase activ-
ity remained unchanged (Figure 5C). As an additional control 
to test the specificity of our system, cells containing the Bcl-w or 
Bcl-2 3′-UTR luciferase reporters were transfected with the oppo-
site Target Protector. Following MYCV394D-ER activation with 
Figure 6. BCL-W expression is selected for in human BL. (A) qRT-PCR analysis (in triplicate) of samples from patients with BL (n = 15) compared with 
normal lymphoid control tissue (n = 7). mRNA levels were normalized to β-actin and presented as 2–ΔΔCt. Bars represent the mean ± SEM. *P = 9.1 × 10–4, 
by t test. (B) Microarray gene expression–profiling data for BCL-W and BCL-2 mRNA in BL (n = 57) compared with normal B cells (n = 49). Bars represent 
the mean ± SEM. Each circle represents 1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. *P = 1.8 × 10–8, by t test. The 
data sets analyzed are listed in Supplemental Table 1. (C) Immunohistochemical analysis for BCL-W and BCL-2 protein was performed on samples from 
patients with BL (n = 26). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2 staining from the same tumor sam-
ple are shown. Original magnification, ×40; scale bars: 200 μm. *P < 0.0001, by t test. For the box and whisker plots, the box represents the 25th and 75th 
percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (D) Protein expression 
was assessed by Western blotting for the indicated proteins in BL and DLBCL cell lines. Controls included tissue from 2 human spleens and purified B 
cells from human peripheral blood.
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We next performed qRT-PCR to evaluate mRNA levels of 
BCL-W and BCL-2 from RNA isolated from formalin-fixed, par-
affin-embedded BL patient samples and normal lymph node 
controls. Strikingly, BCL-W mRNA was overexpressed in the BL 
patient samples compared with expression levels detected in the 
normal tissue (Figure 6A and Supplemental Figure 9). Because 
low or undetectable BCL-2 levels are typical in BL and considered 
during diagnosis, BCL-2 levels were evaluated and showed no 
overexpression compared with normal tissue (Figure 6A and Sup-
plemental Figure 9). As a separate, independent analysis of BCL-W 
mRNA expression in human BL, we evaluated publically available 
microarray gene expression–profiling data (http://www.ncbi.nlm.
nih.gov/geo/). Consistent with our qRT-PCR data, BCL-W was 
significantly overexpressed in BL samples compared with either a 
mixed population of normal B cells or only normal germinal center 
B cells (Figure 6B and Supplemental Figure 10). We also assessed 
BCL-2 mRNA levels and determined that they were not elevated in 
BL cells compared with levels in normal B cells (Figure 6B). These 
data indicate that increased BCL-W mRNA expression is selected 
for in human BL, whereas BCL-2 is not.
To determine whether the increase in BCL-W mRNA resulted in 
increased BCL-W protein expression, we performed immunohisto-
chemical analyses of samples from patients with BL. Blinded scor-
ing by a hematopathologist revealed that expression of BCL-W pro-
tein was a very frequent event in BL. Specifically, 88.5% (23 of 26) of 
the samples had positive staining (≥1 pathologist score) for BCL-W 
(Figure 6C, Table 2, Supplemental Figure 11). Only 15.4% (4 of 26) 
of the samples showed BCL-2 positivity, which was predominantly 
low. Additionally, BCL-W protein was overexpressed in BL cell lines 
compared with normal human splenic tissue and isolated B cells 
(Figure 6D). Evaluation of BCL-W levels in B cell lymphomas from 
Eμ-MYC–Tg mice showed a similarly high frequency of increased 
BCL-W protein expression (Supplemental Figure 12). These results 
indicate that, in addition to murine lymphoma, BCL-W may be a sig-
nificant contributor to the pathogenesis of human BL.
Targeting BCL-W in MYC-driven BL induces apoptosis. Given that 
BCL-W expression is highly selected for in BL, we tested whether 
targeting BCL-W would affect BL cell survival. Because we have 
established a link between Bcl-w and the miR-15 family, which is 
repressed in BL, we hypothesized that increasing levels of the miR-
15 family in these lymphoma cells would decrease BCL-W expres-
sion, leading to apoptosis. To test this, we ectopically expressed the 
miR-15a/16-1 cistron or empty vector as a control in 2 human BL 
cell lines. In both BL cell lines, ectopic expression of miR-15a/16-1 
decreased BCL-W protein expression (Supplemental Figure 13A). 
Reduced levels of BCL-2 protein, which we previously report-
ed occurred with ectopic expression of miR-15a/16-1 in murine 
lymphoma cells (23), were also detected and served as a positive 
control (Supplemental Figure 13A). The forced expression of miR-
15a/16-1 reduced cell growth, total cell numbers, and viability 
(Supplemental Figure 13, B–D). Furthermore, ectopic miR-15a/16-1 
expression induced apoptosis, as evidenced by the appearance of 
cleaved caspase 3 (Supplemental Figure 13A). Therefore, increas-
ing expression of the miR-15 family members that target and down-
regulate BCL-W and BCL-2 induces apoptosis of BL cells.
As an independent approach to specifically test the depen-
dency of BL cells on BCL-W expression, we used a doxycycline- 
4-OHT, luciferase activity decreased to an extent that was similar 
to that seen with no Target Protector present (Figure 5C). In addi-
tion, MYCV394D-ER activation decreased BCL-W and BCL-2 pro-
tein expression levels in the absence of any Target Protector (Fig-
ure 5D). However, BCL-W and BCL-2 levels remained unchanged 
when their respective Target Protectors were present to block the 
miR-15 family binding sites (Figure 5D). Together, these results 
provide direct mechanistic data showing that MYC transcription-
ally upregulates the miR-15 family members that then target and 
decrease the expression of Bcl-w and that this occurs independent-
ly of both MIZ-1 and p53.
BCL-W is overexpressed in human BL. We recently reported 
that the transformation status of the cell dictates whether MYC 
functions as a transcriptional activator or repressor of the miR-
15 family (23). In normal, nontransformed cells, MYC transcrip-
tionally upregulates the miR-15 family, which downregulates 
Bcl-2 and, as we show here, Bcl-w expression, leading to increased 
apoptosis. However, this apoptotic mechanism is inactivated in 
cancer cells, as MYC is converted from a transcriptional activator 
to a transcriptional repressor of the miR-15 family, which would 
allow Bcl-2 and, presumably, Bcl-w levels to be increased in cancer 
cells that overexpressed MYC (23).
We and others have reported that MYC-overexpressing murine 
lymphoma cells have reduced expression of the miR-15 family due 
to MYC-mediated repression (22, 23, 30). We evaluated miR-15a 
expression in formalin-fixed, paraffin-embedded BL patient sam-
ples, which constitutively overexpress MYC due to a MYC trans-
location, a defining feature of this lymphoma (31). As expected, 
miR-15a levels were significantly decreased in BL patient samples 
compared with levels in normal controls (Supplemental Figure 
8A), whereas levels of miR-17-5p, which is induced by MYC in can-
cer cells, were increased in the BL samples (Supplemental Figure 
8B). Therefore, as in murine B cell lymphoma, miR-15a levels are 
reduced in human B cell lymphoma.
Table 2. Characteristics of BL and DLBCL patients for IHC
Characteristic BL DLBCL
Patients n = 26 n = 57
Median age, yr (range) 9 (3–20) 64 (10–93)
Sex, n (percentage)
 Male 17 (65.4%) 35 (61.4%)
 Female 8 (30.8%) 19 (33.3%)
 NA 1 (3.8%) 2 (3.5%)
BCL-W, n (percentage)
 0 3 (11.5%) 7 (12.3%)
 1A 11 (42.3%) 16 (28.1%)
 2A 7 (26.9%) 18 (31.6%)
 3A 5 (19.2%) 16 (28.1%)
BCL-2, n (percentage)
 0 22 (84.6%) 15 (26.3%)
 1A 3 (11.5%) 6 (10.5%)
 2A 1 (3.9%) 14 (24.6%)
 3A 0 (0%) 22 (38.6%)
AWhere duplicate or triplicate samples were available, scores were 
averaged and rounded to the highest integer. NA, not available.
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sion of BCL-W did not show a decrease in 
growth or an increase in caspase 3 cleavage 
after the addition of Dox, which was only 
evident in BL cells expressing the BCL-W 
shRNA alone following the addition of Dox 
(Figure 7, E and F). These data indicate that 
targeting BCL-W in BL, which selects for 
increased BCL-W expression, may be an 
effective therapeutic approach to treat BL.
As an additional test of the require-
ments of BCL-W for BL survival, we took 
a pharmacological approach. The BH3 
mimetic compounds ABT-737 and its ana-
log ABT-263 directly activate apoptosis 
by binding and inhibiting the antiapop-
totic BCL-2 proteins BCL-2, BCL-XL, and 
BCL-W (5). To evaluate the effect of ABT-
737 and ABT-263 on BL, we first deter-
mined the IC50 of each in 2 human BL cell 
lines (Figure 8A). The IC50 for ABT-737 and 
ABT-263 was 500 nM and 1 μM, respec-
tively, for Daudi cells and 250 nM and 2.5 
μM, respectively, for Ramos cells. To deter-
mine whether BCL-W expression alone 
could protect the BL cells from ABT-737 and ABT-263, BCL-W was 
ectopically expressed (Figure 8B and Supplemental Figure 14A) 
and treated the BL cells with the IC50 of each. After 48 hours of 
treatment with the BH3 mimetics, the growth of BL cells express-
ing the control vector was significantly diminished (Figure 8C and 
Supplemental Figure 14B) as a result of increased apoptosis, as 
indicated by the appearance of cleaved caspase 3 (Figure 8B and 
Supplemental Figure 14A). However, cells overexpressing BCL-W 
were not sensitive to ABT-737 or ABT-263, as growth of these cells 
remained unaffected, and no caspase 3 cleavage was detected (Fig-
inducible (Dox-inducible) BCL-W shRNA in 3 human BL cell lines. 
Following the addition of Dox to activate expression of the BCL-W 
shRNA, BCL-W protein expression decreased (Figure 7A). This 
resulted in reduced cell growth in all 3 BL cell lines (Figure 7B). 
The reduction in cell growth was attributed to increased apopto-
sis, as indicated by the increased subG1 DNA content (Figure 7C), 
annexin V positivity (Figure 7D), and caspase 3 cleavage (Figure 
7A). To test whether the negative consequences of BCL-W shRNA 
were specific and not due to off-target effects, BCL-W was ectop-
ically expressed. BL cells with BCL-W shRNA and ectopic expres-
Figure 7. Targeting BCL-W induces apoptosis 
in human BL. (A–D) The indicated human BL 
cell lines were infected with a Dox-inducible 
lentivirus encoding either a BCL-W shRNA 
(shBW) or nontargeting (shNT) control shRNA. 
Following the addition of Dox or DMSO vehicle 
(Veh) control, Western blotting for cleaved 
caspase 3 (A), MTS assays (B, in quadrupli-
cate), and staining for subG1 DNA content (C, 
in triplicate) and annexin V positivity (D, in 
triplicate) were performed. (E and F) Daudi cells 
were doubly infected with the Dox-inducible 
lentivirus expressing either a BCL-W shRNA 
(shBW) or nontargeting (shNT) control shRNA 
and a retrovirus expressing BCL-W (+) or empty 
vector control (–). Following the addition of Dox 
(+) or DMSO vehicle control (–), Western blotting 
for the indicated proteins (E) and MTS assays (F, 
in quadruplicate) were performed. Data shown 
are representative of 2 to 3 independent experi-
ments. Error bars for B–D and F indicate the SD. 
*P < 6.4 × 10–4 (B), *P < 0.025 (C), *P < 0.034 (D), 
and *P < 0.0036 (F), by t test comparing shBW 
and Dox with shBW and vehicle.
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obtained by overexpressing BCL-2 for all experiments with the 
BH3 mimetics (Figure 8 and Supplemental Figure 14). Collec-
tively, these data show that BLs rely on BCL-W expression and 
that increased BCL-W levels in BL cells confer resistance to the 
BH3 mimetics ABT-737 and ABT-263.
BCL-W overexpression in diffuse large B cell lymphoma cor-
relates with worse survival. Given our results with BL, we ques-
tioned whether BCL-W overexpression was specific to BL or 
whether BCL-W may contribute to other human B cell lym-
phomas. We evaluated BCL-W protein levels in diffuse large 
B cell lymphoma (DLBCL) cell lines, which often have dys-
regulated MYC activity. Increased BCL-W protein levels were 
observed in the DLBCL cell lines compared with levels in the 
normal controls (Figure 6D). Additionally, immunohistochem-
ical analysis of DLBCL patient samples showed that BCL-W 
protein was expressed in 87.7% (≥1 pathologist score) of the 
patient samples (Figure 9A, Table 2, Supplemental Figure 15). 
This frequency was consistent with the frequency (73.7%) we 
observed for elevated BCL-2 levels in DLBCL (Supplemental 
Figure 15), a known clinical feature of DLBCL (5). Additional-
ly, while many DLBCL patient samples expressed both BCL-W 
and BCL-2 protein, approximately a quarter of the samples 
(26.3%) expressed only BCL-W protein and not BCL-2 protein 
(Supplemental Figure 15B). Of these samples, the vast majority 
(80%) had high (scoring a 2 or 3) BCL-W levels.
To determine whether the increase in BCL-W protein in DLB-
CL may be due to elevated mRNA levels, we performed qRT-PCR 
on patient samples of DLBCL, with normal lymph nodes and 
spleens serving as control lymphatic tissue. We determined that 
BCL-W was significantly overexpressed in DLBCL compared 
with levels detected in normal tissues (Figure 9B and Supplemen-
tal Figure 16). We obtained similar results for BCL-2 (Figure 9B 
and Supplemental Figure 16), which served as a positive control. 
Furthermore, we evaluated publically available microarray gene 
expression–profiling data on DLBCL to determine whether our 
mRNA results were reflected in larger patient populations (http://
www.ncbi.nlm.nih.gov/geo/). Both BCL-W and BCL-2 were sig-
nificantly overexpressed in DLBCL compared with mixed popula-
tions of normal B cells or only germinal center B cells (Figure 9C 
ure 8, B and C and Supplemental Figure 14, A and B). Additionally, 
4-day kinetics experiments also showed that BL cells with forced 
overexpression of BCL-W were protected from the apoptosis- 
inducing properties of the BH3 mimetics (Figure 8D and Supple-
mental Figure 14C). Finally, increasing concentrations of ABT-737 
and ABT-263 were administered to BL cell lines to determine the 
maximal dose at which the cells overexpressing BCL-W would no 
longer be protected. BL cells with the vector control quickly suc-
cumbed to BH3 mimetic treatment, with all cells dying following 
administration of 10 μM of either compound within 48 hours (Fig-
ure 8E and Supplemental Figure 14D). However, high concentra-
tions (>50 μM) of either compound were necessary to kill the BL 
cells overexpressing BCL-W (Figure 8E and Supplemental Figure 
14D). Results similar to those with BCL-W overexpression were 
Figure 8. Increased expression of BCL-W confers resistance to BL 
cells to BH3 mimetics. (A) The IC50 of the BH3 mimetics ABT-737 and 
ABT-263 for 2 human BL cell lines (Daudi and Ramos) was determined 
using MTS assays (in quadruplicate, 48 h). (B–E) Daudi cells remained 
uninfected (Un) or were retrovirally infected to express empty vector 
(Vec), BCL-W (BW), or BCL-2 (B2). Following treatment with ABT-737 
(+), ABT-263 (+), or DMSO vehicle control (–) at the determined IC50 
(B–D) or the indicated concentrations (E) for 48 hours (B, C, and E) or 
the indicated intervals (D), Western blotting for cleaved caspase 3 (B) 
and MTS assays (C–E, in quadruplicate) were performed. Data shown 
are representative of 2 independent experiments for both inhibitors. 
For data in D and E, experiments with inhibitors were performed at the 
same time but graphed separately, thus the DMSO control data are the 
same. Error bars indicate the SD. *P < 6.67 × 10–6 ABT-737 and #P < 6.05 
× 10–5 ABT-263 (ABT vs. DMSO) (C); *P < 2.69 × 10–4 ABT-737 and #P < 3.7 
× 10–4 ABT-263 (vector with ABT vs. vector, BCL-W, or BCL-2 with DMSO) 
(D); *P < 7.33 × 10–4 ABT-737 and #P < 0.011 ABT-263 (BCL-W or BCL-2 
with ABT vs. BCL-W or BCL-2 with DMSO) (E), by t test.
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survival information. Because BCL-W expression was inversely 
correlated with BCL-2 expression, we assessed the contribution 
of increased BCL-W expression in samples with lower levels of 
BCL-2. Specifically, patient samples were simultaneously strati-
fied on the basis of the median expression of BCL-2 and BCL-W 
into high or low expression groups for each gene. Then, using data 
on those patients with low BCL-2 expression, Kaplan-Meier sur-
vival curves were plotted for the high and low BCL-W expression 
groups. For both data sets, the patients with higher BCL-W levels 
and low BCL-2 levels had significantly worse overall survival than 
did those with lower levels of both BCL-W and BCL-2 (P = 0.0217 
for GSE31312 and P = 0.0419 for GSE10846, log-rank tests, Fig-
ure 9D). Stratification of BCL-W expression for patients with high 
and Supplemental Figure 17). Together, our data show that BCL-W 
may also contribute to DLBCL.
Next, we questioned whether there was a correlation between 
BCL-W and BCL-2 expression in DLBCL. Pearson’s correlations 
were calculated for BCL-W and BCL-2 expression for 2 indepen-
dent data sets. Independently, both data sets showed a negative 
correlation between BCL-W and BCL-2 expression levels in DLBCL 
patient samples (for GSE10846, R = –0.1687 and P = 2.9 × 10–4; for 
GSE31312, R = –0.0948 and P = 3.99 × 10–2). Given that BCL-W was 
frequently overexpressed in DLBCL and survival rates of DLBCL 
are not high, we questioned whether increased expression of 
BCL-W correlated with DLBCL patient survival. To address this, 
the same 2 DLBCL data sets were evaluated, as both contained 
Figure 9. Increased expression of BCL-W in DLBCL correlates with poor patient survival. (A) Immunohistochemical analysis for BCL-W and BCL-2 protein 
was performed on samples from patients with DLBCL (n = 57). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2 
staining from the same 3 tumor samples. Original magnification, ×40; scale bars: 200 μm. For the box and whisker plots, the box represents the 25th 
and 75th percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (B) qRT-PCR 
analysis in triplicate of samples from patients with DLBCL (n = 26) compared with normal lymphoid control tissue (n = 10). mRNA levels were normalized 
to β-actin and are presented as 2–ΔΔCt. Error bars represent the mean ± SEM. **P < 6.03 × 10–5 and *P = 0.014, by t test. (C) Microarray gene expression– 
profiling data for BCL-W and BCL-2 mRNA in DLBCL (n = 319) compared with normal B cells (n = 49). Lines represent the mean ± SEM. Each circle represents 
1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. **P < 2.2 × 10–16 and *P = 9.96 × 10–5, by t test. The data sets analyzed 
are listed in Supplemental Table 1. (D) Patient samples of DLBCL with low BCL-2 from the GSE31312 and GSE10846 data sets were each separated into 2 
groups (BCL-W high and BCL-W low) on the basis of the median expression of BCL-W, and Kaplan-Meier analyses were performed. The P values in D were 
determined by log-rank test.
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mediates apoptosis due to MYC dysregulation (16, 37). There was 
a decreased frequency of p53 pathway inactivation in the lympho-
mas that emerged in Eμ-MYC mice lacking Bcl-w, suggesting a 
decreased selective pressure to inactivate the p53 pathway during 
tumorigenesis. We previously reported that loss of the proapop-
totic BCL-2 family member BAX altered the frequency of p53 
inactivation in MYC-driven lymphomas (17). Together, our data 
highlight a previously unknown function of BCL-W in apoptosis 
triggered by deregulated MYC expression and suggest that BCL-W 
may have cross-talk with the p53 pathway.
To our knowledge, no link has yet been established between 
BCL-W expression and MYC activation. Here, we determined that 
MYC regulates BCL-W expression and identified the underlying 
mechanism through which this occurs. Specifically, we demon-
strated that MYC suppressed the expression of BCL-W inde-
pendently of its interaction with the transcriptional activator MIZ-1 
and of p53, which has been reported to repress the expression 
of the related family members Bcl-2 and Bcl-xl (38, 39). Fur-
thermore, our data revealed that a transcriptionally competent 
MYC was required for the reduction in BCL-W expression. How-
ever, there was no evidence of direct transcriptional activation 
by MYC, suggesting that MYC was indirectly regulating the 
expression of BCL-W. We (here) and others (27–29) have shown 
that Bcl-w is a target of the miR-15 family, which is known to be 
regulated by MYC (40). In addition, we recently demonstrated 
that MYC downregulates the expression of BCL-2 and BCL-XL 
by transcriptionally upregulating the levels of the miR-15 and 
let-7 families, respectively (22, 23). Therefore, we hypothesized 
that MYC was modulating the expression of BCL-W through the 
miR-15 family. Using luciferase reporter assays and site-specific 
small molecules designed to block the miR-15 family from bind-
ing the 3′-UTR of Bcl-w, we provided direct evidence that MYC, 
through the miR-15 family, modulates BCL-W expression. These 
data offer mechanistic evidence of a link between MYC, the miR-
15 family, and BCL-W and, we believe, significantly expand our 
understanding of MYC-mediated apoptosis. Determining which 
transcriptional targets of MYC are responsible for the biological 
consequences of MYC dysregulation and how these are altered 
during cellular transformation provides important insights into 
lymphomagenesis. The data presented here, combined with pre-
vious findings (22, 23, 30, 40), indicate that MYC transcription-
ally activates or represses miR to induce growth or apoptosis and 
that this is altered in cancers.
BCL-2 expression levels did not show a statistically significant 
difference in survival for those who overexpressed both. Next, we 
performed univariate and multivariate Cox regression analyses on 
both stratified data sets (with low BCL-2 expression), since addi-
tional prognostic variables (e.g., patient’s age and tumor stage) 
were available. From the univariate analysis, we determined that 
BCL-W expression, patient’s age, and tumor stage were signifi-
cantly associated with overall survival (Table 3). Considering all 
3 variables, multivariate Cox regression analysis indicated that 
BCL-W expression independently correlated with overall survival 
(Table 3). Together, these results indicate that BCL-W expression 
is a predictive indicator and independent determinant of overall 
survival in DLBCL patients with lower levels of BCL-2.
Discussion
Prior to the current study, BCL-W was not believed to be an 
important contributor to hematopoietic cell survival. However, 
this conclusion was never tested and was based solely on expres-
sion levels and on the observation that no overt hematopoietic cell 
defects were detected in mice lacking Bcl-w (6–9). Here, our study 
has revealed an unexpected and, in our view, significant function 
for BCL-W in B cell survival and MYC-induced lymphomagenesis. 
We also provide important mechanistic insight into the regulation 
of BCL-W expression by MYC in both hematopoietic and nonhe-
matopoietic cells. Most notably, our data provide striking evidence 
of a survival role for BCL-W in both human BL and DLBCL that we 
believe will have significant clinical implications.
Antiapoptotic BCL-2 family members inhibit death signals 
elicited by a number of cellular stressors, including cytokine with-
drawal and activation of MYC (2). Given the dogma regarding 
BCL-W, we were initially surprised that in B cells, loss of Bcl-w 
conferred sensitivity to IL-7 withdrawal and MYC activation. 
Using multiple ex vivo and in vitro approaches, we demonstrated 
that BCL-W significantly contributes to inhibiting MYC-induced 
apoptosis in both hematopoietic and nonhematopoietic cells. Spe-
cifically, in the absence of BCL-W, primary pre–B cells and MEFs 
were considerably more susceptible to MYC-induced apoptosis 
than were cells that had WT BCL-W. Previously, it was reported 
that B cells lacking other antiapoptotic BCL-2 family members 
(BCL-2, BCL-XL, or MCL-1) were more sensitive to MYC-induced 
apoptosis (32–34), whereas loss of proapoptotic BCL-2 family 
members (BIM, BAX, PUMA, or NOXA) conferred resistance to 
MYC-induced apoptosis (17, 18, 35, 36). The p53 pathway also 
Table 3. Analysis of overall survival in patients with DLBCL with low BCL-2 expression
Variables Univariate Multivariate
HR 95% CI P value HR 95% CI P value
GSE10846 Age 1.793 1.113–2.888 0.015 1.898 1.166–3.091 0.010
Tumor stageA 1.851 1.138–3.010 0.012 2.057 1.255–3.372 0.004
BCL-W expression 1.694 1.014–2.832 0.042 1.781 1.055–3.008 0.031
GSE31312 Age 2.252 1.366–3.712 0.001 2.318 1.391–3.861 0.001
Tumor stageA 2.388 1.444–3.949 4.72 × 10–4 2.426 1.468–4.011 5.5 × 10–4
BCL-W expression 1.788 1.081–2.958 0.022 1.696 1.019–2.822 0.042
AEarly stages (I and II) versus late stages (III and IV). HR, hazard ratio.
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taining BCL-W levels in BL for continued cell survival. Additional-
ly, elevated levels of BCL-W alone conferred resistance to BL cell 
lines to the apoptotic effects of the BH3 mimetic compounds ABT-
737 and ABT-263, which target 3 antiapoptotic BCL-2 family mem-
bers. Previously, it was reported that BCL-2 expression correlated 
with sensitivity to ABT-263 in a panel of human non-Hodgkin lym-
phoma cell lines (42) and sensitivity to ABT-737 in human chronic 
lymphocytic leukemia (43, 44), small-cell lung cancer cell lines 
(45), and Eμ-MYC lymphomas (46, 47). In addition, increased 
levels of other antiapoptotic family members, such as MCL-1 
and BCL-XL, have also been shown to confer resistance to ABT-
737 (42). Therefore, our data indicate that expression of BCL-W 
will likely need to be considered and monitored when using BH3 
mimetics for the treatment of lymphomas. Moreover, our data 
suggest that BCL-W may be useful in the diagnosis of BL and aid 
in the development of targeted therapies for this malignancy.
We also investigated BCL-W in DLBCL with respect to BCL-2, a 
known contributor to DLBCL that, when overexpressed, correlates 
with reduced patient survival (5, 48). We determined that many 
samples from DLBCL patients expressed both BCL-W and BCL-2 
protein, but approximately a quarter of the samples only expressed 
BCL-W protein, and of these, the vast majority had high BCL-W 
levels. Furthermore, gene expression profiling of large DLBCL data 
sets also showed an increase in BCL-W mRNA in DLBCL compared 
with normal B cells. We also determined that there was a negative 
correlation between BCL-W and BCL-2 levels in DLBCL, indicating 
that there may be a significant subset of DLBCL cells that preferen-
tially selects for the overexpression of BCL-W rather than BCL-2. 
Importantly, those patients whose lymphoma did preferentially 
select for BCL-W overexpression while BCL-2 levels remained low 
had markedly worse survival rates, and in this context, the level of 
BCL-W was also an independent determinant of overall survival 
in patients with DLBCL. Of note, there was no additive negative 
affect on patient survival when both BCL-2 and BCL-W were over-
expressed, suggesting that lymphoma cell survival is not further 
enhanced once a certain expression level of antiapoptotic BCL-2 
family members is reached. In support of this concept, it has been 
hypothesized that a mechanism of resistance to the BH-3 mimet-
ics involves the upregulation of other antiapoptotic BCL-2 family 
members that are not inhibited by the compounds (5). Therefore, 
our data show that BCL-W expression is an important contributor 
to and predictive indicator of DLBCL. Thus, BCL-W may serve as 
a novel biomarker for BL and more aggressive DLBCL. Collective-
ly, our data indicate that BCL-W is an understudied contributor to 
lymphomas that could be added to the limited list of current pre-
dictive biomarkers to improve prognostication and the develop-
ment of more effective individualized treatment strategies.
Methods
Mice. C57Bl/6 Eμ-MYC-Tg mice (4) were mated with C57Bl/6 Bcl-w+/– 
mice (9) provided by Rosalind Segal (Harvard Medical School, Har-
vard University, Boston, Massachusetts, USA), and their offspring 
were intercrossed to obtain littermate-matched Bcl-w+/+, Bcl-w+/–, 
and Bcl-w–/– Eμ-MYC–Tg mice of both sexes. Only Eμ-MYC–Tg–pos-
itive males were mated to pass on the Tg. For survival studies, mice 
were sacrificed at humane endpoints, and tumors and tissues were 
harvested and analyzed.
With our data showing that BCL-W is a critical mediator of 
MYC-induced apoptosis, we hypothesized that loss of Bcl-w would 
affect lymphomagenesis driven by dysregulated MYC. While 
Bcl-w heterozygosity delayed MYC-induced lymphoma develop-
ment, remarkably, Bcl-w–/– Eμ-MYC–Tg mice developed lympho-
ma with a substantially extended latency compared with that of 
littermate-matched control Eμ-MYC mice. Specifically, Eμ-MYC 
mice lacking both Bcl-w alleles had a mean lifespan that was more 
than 3 times longer than that of their Bcl-w+/+ Eμ-MYC siblings. 
By the time all of the Bcl-w+/+ Eμ-MYC mice had succumbed to 
lymphoma, none of the Bcl-w–/– Eμ-MYC mice had developed 
lymphoma. Reports of the effects of deleting other prosurvival 
BCL-2 family members have shown differing results. For exam-
ple, a Bcl-xl deficiency only slightly delayed Eμ-MYC lymphoma 
development (33), whereas deletion of Bcl-2 did not significantly 
alter lymphomagenesis (34). In contrast, loss of 1 allele of Mcl-1 
profoundly delayed MYC-induced lymphoma development (41). 
Therefore, although there are multiple antiapoptotic BCL-2 fam-
ily members, they do not appear to equally contribute to MYC- 
induced B cell lymphomagenesis.
While lymphoma development was profoundly extended in 
Bcl-w–/– Eμ-MYC mice, loss of Bcl-w did not impact the type of lym-
phoma that emerged. The lymphomas that arose, regardless of 
genotype or time of tumor incidence, were characteristic Eμ-MYC 
pre–B/B cell lymphomas. These observations suggested that the 
B cell populations in which transformation occurs to generate 
lymphomas in the Eμ-MYC mouse model (15) remained unal-
tered by loss of Bcl-w. Indeed, flow cytometric analysis revealed 
that the B cell populations in the spleen and BM of precancerous 
littermates were indistinguishable among the 3 genotypes. Pre-
vious reports using a transplant model with fetal liver–derived 
stem cells from Eμ-MYC Bcl-2–/– (34) or Eμ-MYC Bcl-xl–/– (33) mice 
documented reduced immature and mature or pro–B and pre–B 
cells, respectively, which is consistent with the cell types in which 
these proteins predominantly function (2). Despite having similar 
biochemical functions, our data support the concept that specif-
ic antiapoptotic BCL-2 family members are more important than 
other family members in different cell types or stages of differen-
tiation (5). Knowing when and how individual prosurvival BCL-2 
proteins are relied on during neoplastic transformation may pro-
vide additional strategies for treating MYC-driven lymphoma.
MYC is overexpressed and/or dysregulated in the majority of 
human cancers (3); therefore, we believe that our results demon-
strating an essential role for BCL-W in MYC-induced lymphom-
agenesis have significant implications for cancer biology and 
therapy. Importantly, we exposed a previously unknown connec-
tion between BCL-W and the MYC-driven human BL, a lympho-
ma for which no other antiapoptotic BCL-2 family member has 
been linked. Using a combination of approaches, we showed that 
increased BCL-W expression is highly selected for in BL. Specif-
ically, 88.5% of the patient samples expressed BCL-W protein, 
whereas only 15.4% expressed BCL-2. These data were supported 
by analyses of BCL-W and BCL-2 mRNA from BL patient samples, 
which showed that elevated levels of BCL-W mRNA were prefer-
entially selected for, but BCL-2 was not. Furthermore, we demon-
strate that knocking down BCL-W expression in human BL cell 
lines resulted in apoptosis, highlighting the importance of main-
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cue experiments, retroviral vectors were generated to express BCL-W 
(MSCV-BCLW-IRES-RFP) or BCL-2 (MSCV-BCL2-IRES-RFP).
Cells, infection, and transfection. Daudi, Ramos, Raji, Su-DHL-6, and 
NIH3T3 cells were cultured as described by the American Type Culture 
Collection (ATCC). OCI-Ly-19 and OCI-Ly-3 cells were cultured in 
RPMI-1640 containing 10% FBS. All cell lines were negative for MYCo-
plasma. MEFs were generated and cultured as previously described 
(37). Primary murine pre–B cell cultures were generated as previous-
ly described (16). Briefly, BM was harvested from 8- to 10-week-old 
Bcl-w+/+, Bcl-w+/–, and Bcl-w–/– littermate-matched mice or 4- to 6-week-
old littermate-matched Eμ-MYC–Tg mice (prior to lymphoma develop-
ment) with 1, 2, or no Bcl-w alleles. After red blood cell lysis, BM cells 
were cultured in RMPI supplemented with 10 ng/ml IL-7, 20% FBS, 55 
μM β-mercaptoethanol, 2 mM glutamine, and penicillin-streptoMYCin. 
Primary pre–B cells and MEFs were infected with bicistronic retroviral 
vectors (described above) in the presence of 8 μg/ml polybrene as pre-
viously described (37). GFP-positive pre–B cells were isolated by fluo-
rescence-activated cell sorting. Human BL cell lines were infected with 
Dox-inducible lentiviral vectors (see above) expressing either a non-
targeting shRNA or BCL-W–targeting shRNA and/or retroviral vectors 
expressing either BCL-W or BCL-2 cDNA or empty vector control. p53–/– 
MEFs were transfected using Lipofectamine 2000 (Invitrogen, Thermo 
Fisher Scientific) with 200 nM miScript Target Protector for Bcl-w or 
Bcl-2 (QIAGEN) according to the manufacturers’ protocols.
Western blotting. Whole-cell protein lysates were generated, and 
equal amounts of protein per lane were Western blotted as previ-
ously described (16). The following antibodies were used: p19ARF 
(GTX200780; GeneTex); p53 (Ab-7; Calbiochem); BCL-W (31H4, 
product no. 2724) and cleaved caspase 3 (Asp175, product no. 9661) 
(both from Cell Signaling Technology); BCL-2 (3F11) and BCL-XL 
(44/BCL-X) (both from BD Bioscience); MCL-1 (200-401-CR9; 
Rockland); MYC (9E10; EMD Millipore); and β-actin (AC-15; Sigma- 
Aldrich). p53 cDNA was sequenced as previously described (16).
Growth and apoptosis analyses. For IL-7 deprivation experiments, 
BM-derived primary pre–B cells were washed twice with PBS and 
resuspended in complete media (described above) without IL-7. To 
activate MYCER, 1 μM 4-hydroxytamoxifen (4-OHT; Sigma-Aldrich) 
or vehicle control (EtOH) was added to culture media. Population dou-
blings, cell numbers, and/or viability were determined by trypan blue 
dye exclusion (in triplicate) and proliferation by MTT (Sigma-Aldrich; 
560 nm) or MTS (Promega; 490 nm) assays (in quadruplicate). Apopto-
sis was evaluated by Western blotting for cleaved caspase 3 (described 
above) and flow cytometry following propidium iodide (sub-G1/apop-
totic DNA content) or annexin V/7-AAD staining (both in triplicate) as 
previously reported (52). The ABT-737 and ABT-263 compounds were 
obtained from Selleckchem and reconstituted with DMSO.
qRT-PCR. Total RNA was isolated from cell lines using TRIzol 
(Invitrogen, Thermo Fisher Scientific) or the RecoverAll Total Nucleic 
Acid Isolation Kit for FFPE tissue (Thermo Fisher Scientific) accord-
ing to the manufacturer’s protocols. cDNA was generated and SYBR 
Green (SABiosciences, QIAGEN) and TaqMan MicroRNA (Applied 
Biosystems) assays were performed in triplicate to measure mRNA 
and miR, respectively, as previously described (53, 54). qPCR of lym-
phoma TissueScan cDNA arrays (OriGene) was completed according 
to the manufacturer’s protocol. mRNA and miR expression was nor-
malized to β-actin and RNU6b, respectively, and presented as 2–ΔΔCt. 
Primer sequences for mouse and human BCL-W, BCL-2, BCL-XL, 
Lymphoma phenotype and B cell development analysis. Spleno-
cytes and BM from littermates (prior to lymphoma development for 
Eμ-MYC–Tg mice) or lymphoma cells were analyzed by flow cytome-
try following incubation with fluorochrome-linked antibodies as pre-
viously reported (49, 50).
Patient samples and tissue acquisition. Normal human B cells were 
purified from leukoreduction filters obtained from the Red Cross 
using the IMag Human B Lymphocyte Enrichment Set (BD Biosci-
ences). Deidentified fresh spleens were obtained from the Coopera-
tive Human Tissue Network at Vanderbilt University Medical Center 
(VUMC) (Nashville, Tennessee, USA). For immunohistochemical 
analysis of DLBCL, formalin-fixed, paraffin-embedded (FFPE) tis-
sues were selected from archival pathology materials on the basis of 
a documented large B cell diagnosis. Two separate tissue microarrays 
(TMAs) were constructed using 2-mm diameter cores from 35 sepa-
rate specimens represented in duplicate and 20 separate specimens 
represented in triplicate, respectively. In addition, 10 samples with 
high-grade morphologic features were examined as individual slides. 
Fifty-seven DLBCL samples were considered evaluable and included 
in the analyses. For qRT-PCR analysis of DLBCL, TissueScan cDNA 
arrays containing 26 samples from patients with DLBCL and 10 nor-
mal lymphoid tissue controls were obtained from OriGene. For immu-
nohistochemical analysis of BL, slides from 28 deidentified patients 
diagnosed with BL were obtained from St. Jude Children’s Research 
Hospital (Memphis, Tennessee, USA). Twenty-six BL samples were 
considered evaluable and included in the analyses. Patient character-
istics are listed in Table 2, and details on how the pathologist scored 
IHC are provided in Supplemental Figures 11 and 15. For qRT-PCR 
analysis of BL samples, 15 FFPE BL samples and 7 FFPE normal lym-
phoid control tissues were obtained from Thomas Jefferson University 
(Philadelphia, Pennsylvania, USA). 
IHC. Immunohistochemical analysis was performed on 4-μm 
sections from BM preparations with anti–BCL-W (sc-6172; Santa Cruz 
Biotechnology Inc.) and anti–BCL-2 (PA0117; Leica Biosystems). A 
Leica BOND-MAX stainer was used with the Bond Polymer Refine 
detection system for visualization (Leica Biosystems). Expression 
levels were scored by a practicing board-certified hematopathologist 
(ASK) on a 0–3 point scale in a blinded fashion and scoring only the 
neoplastic cells. After unblinding, scores for the replicate samples on 
the TMAs were averaged and a final score obtained.
Vectors. MSCV-MYCER-IRES-GFP, MSCV-MYCΔMBIIER-IRES- 
GFP (MYC box II deletion mutant), and MSCV-MYCV394D-ER-IRES-
GFP (MYC:MIZ-1 interaction mutant) bicistronic retroviral vectors have 
been previously described (23, 37). Luciferase reporter plasmids were 
constructed by cloning a 60-mer of the 3′-UTR of Bcl-w containing the 
predicted miR-15 family target sequence into pMIR-REPORT (Invitro-
gen, Thermo Fisher Scientific). Luciferase reporters containing mutat-
ed miR binding sites were similarly generated by cloning a 60-mer with 
a mutated (base substitutions) target sequence to prevent the miR-15 
family from binding the 3′-UTR of Bcl-w into pMIR-REPORT. Both 
luciferase plasmids for the Bcl-2 3′-UTR have previously been report-
ed (23). For luciferase assays, a reporter plasmid encoding β-gal was 
used for transfection normalization (Invitrogen, Thermo Fisher Scien-
tific). For knockdown experiments, nontargeting and BCL-W shRNA 
sequences were cloned into the pInducer Dox-inducible shRNA system 
(51). To induce shRNA expression, cells were treated with 1 μg/ml Dox 
(Sigma-Aldrich) or vehicle control (DMSO). For overexpression and res-
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the basis of the median age. Survival analyses were carried out using 
the R survival package, version 3.2.3.
Statistics. A 1-tailed Student’s t test was used when comparing 2 
groups. One-way ANOVA was performed with Bonferroni’s correction 
when comparing multiple groups. Survival curves were compared by 
log-rank tests. The figure legends indicate the statistical tests used, 
which groups were compared, and when values represent the mean ± 
SD or the mean ± SEM. Univariate and multivariate survival analyses 
were analyzed by Cox proportional hazards regression models. The 
Pearson’s correlation coefficient was used to determine the associa-
tion between BCL-W and BCL-2 expression. A P value of less than 0.05 
was considered statistically significant.
Study approval. All studies using mice and deidentified human 
samples complied with state and federal guidelines and were approved 
by the IACUCs and/or IRBs of VUMC and Thomas Jefferson Universi-
ty. All deidentified human tissues were obtained from the Cooperative 
Human Tissue Network of VUMC, St. Jude Children’s Research Hos-
pital, or Thomas Jefferson University.
Author contributions
CMA and CME designed the research studies. CMA performed 
the experiments. ASK performed the pathological analyses. RM 
completed the bioinformatics analyses. JKC and JZG provided 
samples from patients with BL for immunohistochemical and 
mRNA analyses, respectively. CMA, ASK, RM, and CME wrote 
the manuscript. All authors reviewed and edited the manuscript.
Acknowledgments
We thank Pia Arrate, Kelli Boyd, and Cindy Lowe for their techni-
cal assistance; Rosalind Segal for the Bcl-w mice; the Encyclopedia 
of DNA Elements (ENCODE) Consortium and production labo-
ratories; and members of the Eischen laboratory for their helpful 
discussions. TMAs and IHC were performed by the Translational 
Pathology Shared Resource at VUMC. Support was provided by NCI 
for F31CA165728 (CMA), R01CA177786 (CME), R01CA148950 
(CME), and the NCI Cancer Center support grant P30CA056036.
Address correspondence to: Christine M. Eischen, Thomas Jef-
ferson University, Department of Cancer Biology, 233 South 
10th Street, Philadelphia, Pennsylvania 19107, USA. Phone: 215. 
503.5692; E-mail: christine.eischen@jefferson.edu.
MCL-1, and β-actin mRNA expression were obtained from the Harvard 
Medical School Primer Bank (55).
Luciferase assays. p53–/– MEFs expressing the 4-OHT–inducible 
WT MYCER, MYCΔMBII-ER, or MYCV394D-ER were transfected 
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designed to block miR-15 family binding sites in the 3′-UTR of Bcl-w 
and Bcl-2. Luciferase and β-gal activity was measured 24 hours after 
MYCER activation as previously described (23).
Microarray gene expression analysis. Microarray gene expression 
profiling data for BL, DLBCL, and normal human B cells (germinal 
center centroblasts and centrocytes, naive B cells, and memory B 
cells) were generated on the Affymetrix Human Genome U133 Plus 
2.0 platform following the standard Affymetrix protocol. Data sets 
(summarized in Supplemental Table 1) were downloaded from the 
NCBI’s Gene Expression Omnibus (GEO) database (56) or from the 
authors’ website. BL, DLBCL, and normal B cell CEL files were nor-
malized using a robust multiarray average algorithm (57). Batch effects 
were adjusted using ComBat (58). Probe sets were averaged to obtain 
a single-expression intensity measure per gene per array. Differential 
expression was measured by an unpaired, 1-tailed t test. All analyses 
were carried out in R, version 3.2.3.
Patient survival and correlation analyses. Two microarray gene 
expression–profiling data sets for DLBCLs (59, 60) were generated 
on the Affymetrix Human Genome U133 Plus 2.0 platform following 
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median expression of BCL-2 and BCL-W into high or low expression 
groups for each gene. Then, using data on those patients with low 
BCL-2 expression, Kaplan-Meier survival curves were plotted for the 
high and low BCL-W expression groups and compared using log-rank 
tests. Univariate and multivariate Cox proportional hazards regres-
sion analyses for overall DLBCL survival outcomes based on BCL-W 
expression when BCL-2 expression was low were also performed. 
Tumor stages were stratified into lower (I and II) and higher (III and 
IV) stages. Patients were divided into lower and higher age groups on 
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